Aldeyra Therapeutics (ALDX) Stock Forecast, Price Target & Predictions
ALDX Stock Forecast
Aldeyra Therapeutics stock forecast is as follows: an average price target of $11.00 (represents a 112.36% upside from ALDX’s last price of $5.18) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ALDX Price Target
ALDX Analyst Ratings
Aldeyra Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 03, 2024 | Justin Kim | Oppenheimer | $12.00 | $5.14 | 133.46% | 131.66% |
Apr 03, 2024 | Justin Kim | Oppenheimer | $10.00 | $3.55 | 181.69% | 93.05% |
Apr 02, 2024 | Matt Caufield | H.C. Wainwright | $10.00 | $3.27 | 205.81% | 93.05% |
Aldeyra Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 3 |
Avg Price Target | - | $12.00 | $10.67 |
Last Closing Price | $5.18 | $5.18 | $5.18 |
Upside/Downside | -100.00% | 131.66% | 105.98% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Apr 03, 2024 | Oppenheimer | - | Outperform | Upgrade |
Jun 09, 2022 | Citigroup | Buy | Buy | Hold |
Aldeyra Therapeutics Financial Forecast
Aldeyra Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $392.62K | - |
Avg Forecast | - | - | - | - | $33.17M | - | - | $1.20M | $3.00M | $-46.00 |
High Forecast | - | - | - | - | $33.17M | - | - | $1.20M | $3.00M | $-46.00 |
Low Forecast | - | - | - | - | $33.17M | - | - | $1.20M | $3.00M | $-46.00 |
# Analysts | - | - | - | - | 4 | - | - | 2 | 4 | 2 |
Surprise % | - | - | - | - | - | - | - | - | 0.13% | - |
Aldeyra Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | - | - | 2 | 4 | 2 |
EBITDA | - | - | - | - | - | - | - | - | $-13.97M | $-15.31M |
Avg Forecast | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - |
Aldeyra Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | - | - | 2 | 4 | 2 |
Net Income | - | - | - | - | - | - | - | - | $-5.45M | $-15.79M |
Avg Forecast | $-15.45M | $-15.45M | $-13.67M | $-13.67M | $9.61M | $-14.68M | $-12.26M | $-6.57M | $-6.57M | $-15.62M |
High Forecast | $-15.45M | $-15.45M | $-13.67M | $-13.67M | $9.61M | $-9.40M | $-12.26M | $-6.57M | $-5.63M | $-15.62M |
Low Forecast | $-15.45M | $-15.45M | $-13.67M | $-13.67M | $9.61M | $-17.03M | $-12.26M | $-6.57M | $-6.88M | $-15.62M |
Surprise % | - | - | - | - | - | - | - | - | 0.83% | 1.01% |
Aldeyra Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | - | - | 2 | 4 | 2 |
SG&A | - | - | - | - | - | - | - | - | $1.80M | $2.55M |
Avg Forecast | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - |
Aldeyra Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | - | - | 2 | 4 | 2 |
EPS | - | - | - | - | - | - | - | - | $-0.09 | $-0.27 |
Avg Forecast | $-0.26 | $-0.26 | $-0.23 | $-0.23 | $0.16 | $-0.25 | $-0.21 | $-0.11 | $-0.11 | $-0.26 |
High Forecast | $-0.26 | $-0.26 | $-0.23 | $-0.23 | $0.16 | $-0.16 | $-0.21 | $-0.11 | $-0.09 | $-0.26 |
Low Forecast | $-0.26 | $-0.26 | $-0.23 | $-0.23 | $0.16 | $-0.29 | $-0.21 | $-0.11 | $-0.12 | $-0.26 |
Surprise % | - | - | - | - | - | - | - | - | 0.84% | 1.03% |
Aldeyra Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
LXRX | Lexicon Pharmaceuticals | $1.21 | $6.00 | 395.87% | Buy |
INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
ETNB | 89bio | $9.29 | $22.00 | 136.81% | Buy |
GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
ALDX | Aldeyra Therapeutics | $5.18 | $11.00 | 112.36% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
ETON | Eton Pharmaceuticals | $8.35 | $13.00 | 55.69% | Buy |
MCRB | Seres Therapeutics | $0.81 | $1.25 | 54.32% | Buy |
IBRX | ImmunityBio | $5.20 | $8.00 | 53.85% | Buy |
ARDX | Ardelyx | $5.89 | $8.75 | 48.56% | Buy |
PHAT | Phathom Pharmaceuticals | $18.94 | $25.83 | 36.38% | Buy |
TARS | Tarsus Pharmaceuticals | $46.21 | $62.00 | 34.17% | Buy |
BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
HOOK | HOOKIPA Pharma | $3.76 | $3.00 | -20.21% | Buy |
ALDX Forecast FAQ
Is Aldeyra Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Aldeyra Therapeutics (ALDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ALDX's total ratings.
What is ALDX's price target?
Aldeyra Therapeutics (ALDX) average price target is $11 with a range of $10 to $12, implying a 112.36% from its last price of $5.18. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aldeyra Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ALDX stock, the company can go up by 112.36% (from the last price of $5.18 to the average price target of $11), up by 131.66% based on the highest stock price target, and up by 93.05% based on the lowest stock price target.
Can Aldeyra Therapeutics stock reach $8?
ALDX's average twelve months analyst stock price target of $11 supports the claim that Aldeyra Therapeutics can reach $8 in the near future.
What are Aldeyra Therapeutics's analysts' financial forecasts?
Aldeyra Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $34.37M (high $34.37M, low $34.37M), average EBITDA is $0 (high $0, low $0), average net income is $-23.904M (high $-18.618M, low $-26.253M), average SG&A $0 (high $0, low $0), and average EPS is $-0.402 (high $-0.313, low $-0.442). ALDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-58.226M (high $-58.226M, low $-58.226M), average SG&A $0 (high $0, low $0), and average EPS is $-0.98 (high $-0.98, low $-0.98).
Did the ALDX's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Dec 2023), Aldeyra Therapeutics's revenue was $392.62K, missing the average analysts' forecast of $3M by -86.91%. The company's EBITDA was $-13.975M, beating the average prediction of $0 by 0%. Aldeyra Therapeutics's net income was $-5.449M, missing the average estimation of $-6.566M by -17.01%. The company's SG&A was $1.8M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-0.0924, missing the average prediction of $-0.111 by -16.40%